Acurx Pharmaceuticals

Intangible assets: moderate. Ibezapolstat is first‑in‑class with FDA Fast Track and QIDP (adds regulatory exclusivity upon approval).

Patent coverage includes legacy composition claims and newer patents that specifically cover CDI treatment with reduced recurrence and microbiome benefits, with expiries cited into the 2030s and a method‑of‑use patent reported through 2042. Scientific validation of the PolC target was published with structural biology that supports a differentiated class.

Switching costs: low to moderate. Physicians can substitute oral antibiotics readily; switching will depend on superior recurrence outcomes and payer coverage. Network effects: none. Cost advantage: uncertain; CDI therapy economics are driven by outcomes and payer policies more than manufacturing cost.

Efficient scale: limited; the CDI market is meaningful but bounded, with entrenched standards and microbiome competitors. Moat durability is contingent on pivotal efficacy and health‑economic differentiation; otherwise, generics and existing products pressure adoption.